In a report released today, Paul Choi from Goldman Sachs reiterated a Sell rating on FibroGen (FGEN – Research Report). The company’s shares opened today at $16.65.
Choi covers the Healthcare sector, focusing on stocks such as FibroGen, Vir Biotechnology, and PTC Therapeutics. According to TipRanks, Choi has an average return of 6.2% and a 49.22% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for FibroGen with a $27.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on FibroGen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $34.37 million and a GAAP net loss of $59.5 million. In comparison, last year the company earned a revenue of $16.54 million and had a GAAP net loss of $134.08 million
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Read More on FGEN:
- FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
- FibroGen announces non-dilutive term loan financing for up to $150M
- FibroGen put buyer realizes 12% same-day gains
- FibroGen to Report First Quarter 2023 Financial Results
- FibroGen completes patient enrollment in ZEPHYRUS-2
